Correlation Between Anebulo Pharmaceuticals and TC BioPharm

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Anebulo Pharmaceuticals and TC BioPharm at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Anebulo Pharmaceuticals and TC BioPharm into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Anebulo Pharmaceuticals and TC BioPharm Holdings, you can compare the effects of market volatilities on Anebulo Pharmaceuticals and TC BioPharm and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Anebulo Pharmaceuticals with a short position of TC BioPharm. Check out your portfolio center. Please also check ongoing floating volatility patterns of Anebulo Pharmaceuticals and TC BioPharm.

Diversification Opportunities for Anebulo Pharmaceuticals and TC BioPharm

0.33
  Correlation Coefficient

Weak diversification

The 3 months correlation between Anebulo and TCBP is 0.33. Overlapping area represents the amount of risk that can be diversified away by holding Anebulo Pharmaceuticals and TC BioPharm Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on TC BioPharm Holdings and Anebulo Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Anebulo Pharmaceuticals are associated (or correlated) with TC BioPharm. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of TC BioPharm Holdings has no effect on the direction of Anebulo Pharmaceuticals i.e., Anebulo Pharmaceuticals and TC BioPharm go up and down completely randomly.

Pair Corralation between Anebulo Pharmaceuticals and TC BioPharm

Given the investment horizon of 90 days Anebulo Pharmaceuticals is expected to generate 0.57 times more return on investment than TC BioPharm. However, Anebulo Pharmaceuticals is 1.77 times less risky than TC BioPharm. It trades about 0.0 of its potential returns per unit of risk. TC BioPharm Holdings is currently generating about -0.32 per unit of risk. If you would invest  164.00  in Anebulo Pharmaceuticals on December 28, 2024 and sell it today you would lose (24.00) from holding Anebulo Pharmaceuticals or give up 14.63% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy95.0%
ValuesDaily Returns

Anebulo Pharmaceuticals  vs.  TC BioPharm Holdings

 Performance 
       Timeline  
Anebulo Pharmaceuticals 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Anebulo Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong technical and fundamental indicators, Anebulo Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.
TC BioPharm Holdings 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days TC BioPharm Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's fundamental drivers remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Anebulo Pharmaceuticals and TC BioPharm Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Anebulo Pharmaceuticals and TC BioPharm

The main advantage of trading using opposite Anebulo Pharmaceuticals and TC BioPharm positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Anebulo Pharmaceuticals position performs unexpectedly, TC BioPharm can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in TC BioPharm will offset losses from the drop in TC BioPharm's long position.
The idea behind Anebulo Pharmaceuticals and TC BioPharm Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Other Complementary Tools

Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance